Eli Lilly receives FDA approval for once-weekly basal insulin Onswik
What happened
Eli Lilly received U.S. Food and Drug Administration approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes. Onswik, chemically known as insulin efsitora alfa-gobe, is intended to be used with diet and exercise to help control high blood sugar. The drug met its main goal by showing A1C reductions comparable to daily basal insulin glargine.
From financialcontent.com
Why it matters
The approval strengthens Eli Lilly’s diabetes franchise by lowering the dosing burden for patients. This once-weekly option provides a commercial edge as Eli Lilly competes with rivals, such as Novo Nordisk, in the basal insulin market.
Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
From financialcontent.com
Who's involved
- Eli Lilly and CompanyPharmaceutical company that received approval for the new basal insulin drug.
- FDARegulatory body that granted approval for Eli Lilly's new insulin product.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Eli Lilly and CompanySpeculative
Eli Lilly might see increased revenue from its diabetes franchise due to the once-weekly dosing option.
Keep exploring
Part of
Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Also in this story
- Novo Nordisk expanded its pediatric label franchise on September 15, 2026.
- Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.
- New competing products are launching in the weight-loss market, intensifying the competition between Eli Lilly and its rivals.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector, seeking Australian regulatory approval.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Global market sentiment is being influenced by geopolitical conflict in the Middle East, impacting the competitive landscape of diabetes and obesity drug companies like Novo Nordisk and Eli Lilly.
- BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.